June 27: The Week in Cancer News
Low-dose aspirin reduces cancer risk for people with Lynch syndrome, and breast cancer survivors may have lower risk for Alzheimer’s than the general public.
Progress Against Cancer
Low-dose aspirin reduces cancer risk for people with Lynch syndrome, and breast cancer survivors may have lower risk for Alzheimer’s than the general public.
For June 2025, the editors of AACR's journals highlighted studies on pancreatic cancer interception, breast cancer risk prediction, and more.
Cancer Today's 2025 summer issue covers the expanded use of neoadjuvant immunotherapy, PSMA-targeted therapy for prostate cancer, and more.
A study suggests that modifying a patient’s gut microbiome could make their cancer more likely to respond to CAR T-cell therapy.
The FDA has approved datopotamab deruxtecan-dlnk for certain patients with non-small cell lung cancer. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to datopotamab deruxtecan-dlnk (Datroway) for the treatment of adult...
Surgery to remove fallopian tubes can lower ovarian cancer risk, and NIH staff cuts lead to delays for patients with no other treatment options.
The FDA has approved tafasitamab-cxix for certain patients with follicular lymphoma. The U.S. Food and Drug Administration (FDA) has approved tafasitamab-cxix (Monjuvi) in combination with lenalidomide (Revlimid) and rituximab (Rituxan) for the treatment of...
Several new studies show how exercise can extend cancer patients’ survival, reduce the risk of recurrence, and improve quality of life.
Researchers explore the causes of lung cancer in never-smokers, and findings support start to colonoscopy screening at age 45.
The FDA has approved pembrolizumab for certain patients with previously untreated head and neck cancer. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda) for the treatment of adult patients with resectable...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More